Stockscreener 앱 받기
9.84
9.23%
-1.00
시간 외 거래:
10.29
0.45
+4.57%
전일 마감가:
$10.84
열려 있는:
$10.84
하루 거래량:
1.01M
Relative Volume:
1.03
시가총액:
$1.59B
수익:
-
순이익/손실:
$-274.18M
주가수익비율:
-5.7269
EPS:
-1.7182
순현금흐름:
$-198.33M
1주 성능:
-27.86%
1개월 성능:
-40.33%
6개월 성능:
+1.76%
1년 성능:
-18.20%
1일 변동 폭
$9.84
$11.05
1주일 범위
$9.84
$13.05
52주 변동 폭
$8.33
$21.00
Neumora Therapeutics Inc Stock (NMRA) Company Profile
명칭
Neumora Therapeutics Inc
전화
(857) 760-0900
주소
490 ARSENAL WAY, SUITE 200, WATERTOWN
NMRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| NMRA | 9.84 | 1.59B | 0 | -274.18M | -198.33M | -1.7182 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-12 | 개시 | Deutsche Bank | Hold |
| 2023-10-10 | 개시 | BofA Securities | Buy |
| 2023-10-10 | 개시 | Guggenheim | Buy |
| 2023-10-10 | 개시 | JP Morgan | Overweight |
| 2023-10-10 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-10 | 개시 | Stifel | Buy |
| 2023-10-10 | 개시 | William Blair | Outperform |
모두보기
Neumora Therapeutics Inc 주식(NMRA)의 최신 뉴스
Financial Comparison: Neumora Therapeutics (NMRA) and Its Rivals - Defense World
HC Wainwright Issues Pessimistic Forecast for NMRA Earnings - Defense World
Analysts Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) Target Price at $21.67 - Defense World
Equities Analysts Set Expectations for NMRA FY2024 Earnings - Defense World
FY2024 EPS Estimate for Neumora Therapeutics Cut by Analyst - MarketBeat
HC Wainwright Analysts Lower Earnings Estimates for NMRA - MarketBeat
This biotech’s stock may double on treatment for depression, says Mizuho - MarketWatch
SoftBank Group Corp.'s Strategic Reduction in Neumora Therapeuti - GuruFocus.com
Neumora Therapeutics (NASDAQ:NMRA) Announces Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $21.67 Average PT from Analysts - MarketBeat
Neumora Therapeutics Reports Q3 2024 Financial Results - TipRanks
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.
Where Do Analysts Think The Neumora Therapeutics Inc (NASDAQ: NMRA) Is Going - Stocks Register
Neumora Therapeutics (NMRA) to Release Quarterly Earnings on Tuesday - Defense World
Objective long/short (NMRA) Report - Stock Traders Daily
Neumora Therapeutics downgraded to Neutral from Overweight at JPMorgan - MSN
What You Didn’t Know About Neumora Therapeutics Inc (NASDAQ: NMRA) This Week - Stocks Register
Neumora Therapeutics to Participate in Upcoming Conferences in November - The Manila Times
Neumora Therapeutics (NASDAQ:NMRA) Shares Gap DownHere's Why - MarketBeat
Neumora Therapeutics (NMRA) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
Auour Investments LLC Takes $3.30 Million Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For TuesdayCognex (NASDAQ:CGNX) - Benzinga
Neumora Therapeutics (NASDAQ:NMRA) Downgraded by JPMorgan Chase & Co. to Neutral - MarketBeat
JPMorgan downgrades Neumora stock, warns of potential downside without data clarity - Investing.com UK
Critical Analysis: Neumora Therapeutics (NMRA) and The Competition - Defense World
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - The Manila Times
(NMRA) On The My Stocks Page - Stock Traders Daily
Neumora Therapeutics (NASDAQ:NMRA) Trading Down 4.5%Time to Sell? - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Down Following Insider Selling - Defense World
SG Americas Securities LLC Lowers Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Bleakley Financial Group LLC Sells 1,966 Shares of Vanguard Mid-Cap Growth ETF (NYSEARCA:VOT) - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by SG Americas Securities LLC - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Director Sells $239,254.47 in Stock - MarketBeat
Neumora Therapeutics director Matthew Fust sells $370,961 in stock - Investing.com India
Neumora Therapeutics director Matthew Fust sells $370,961 in stock By Investing.com - Investing.com South Africa
Neumora Therapeutics (NASDAQ:NMRA) Rating Reiterated by Needham & Company LLC - MarketBeat
(NMRA) Investment Analysis - Stock Traders Daily
This trade activity should not be overlooked: Neumora Therapeutics Inc. (NMRA) - SETE News
Neumora Therapeutics: A Story Of A Class II Biotech (NASDAQ:NMRA) - Seeking Alpha
Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Down After Insider Selling - Defense World
Have you been able to find a good deal on Neumora Therapeutics Inc.’s shares? - US Post News
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by The Manufacturers Life Insurance Company - MarketBeat
Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline - Yahoo Finance
Neumora Therapeutics executive sells over $200k in company stock By Investing.com - Investing.com Australia
Neumora Therapeutics executive sells over $200k in company stock - Investing.com India
Neumora Therapeutics Inc (NMRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):